1 AIMS dyskinesia score was also reduced in the 40 mg/day
2 AIMS OF THE STUDY: To compare sociodemographic, clinical
3 AIMS was delivered by nurses during routine clinic visit
4 AIMS/HYPOTHESIS: We have previously shown the implicatio
5 AIMS: Doxorubicin (DOX), a widely used anticancer agent,
6 AIMS: The mdx mouse has proven to be useful in understan
7 AIMS: The recent and ongoing worldwide expansion in prev
8 AIMS: This two phase study aimed to explore health care
9 AIMS: To (i) estimate the diagnostic accuracy of ThermoS
10 AIMS: To assess in a pilot study whether (i) Allergy Dia
11 AIMS: To compare the risk of vascular disease, HbA1c and
12 AIMS: To determine the incidence of functional stroke mi
13 AIMS: To identify neural network differences in the hemo
14 AIMS: To quantify the volume, type and costs, in a Unite
15 Additionally,
AIMS was cost-effective (ie, dominant: cheaper and more
16 BACKGROUND
AND AIMS: Diabetes mellitus is likely to have a major effect
17 BACKGROUND
AND AIMS: Duodenoscopes have been implicated in the transmis
18 BACKGROUND
AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB
19 BACKGROUND
AND AIMS: Immunosuppressive therapy for inflammatory bowel d
20 BACKGROUND
AND AIMS: Proteomics holds promise for individualizing cance
21 BACKGROUND
AND AIMS: The IL28B genotype has been linked to sustained vi
22 BACKGROUND
AND AIMS: The mammalian intestinal epithelium self-renews ra
23 BACKGROUND
AND AIMS: The risk of hepatocellular cancer (HCC) after sust
24 BACKGROUND
AND AIMS: Tumor necrosis factor (TNF) is a cytokine that pro
25 BACKGROUND &
AIMS: 5-hydroxytryptamine receptor (5-HT(4)R) agonists p
26 BACKGROUND &
AIMS: A diagnosis of celiac disease is made based on cli
27 BACKGROUND &
AIMS: A reduction in portal pressure gradient (PPG) to <
28 BACKGROUND &
AIMS: A system is needed to determine the risk of patien
29 BACKGROUND &
AIMS: A variety of fecal immunochemical tests (FITs) for
30 BACKGROUND &
AIMS: Accurate optical analysis of colorectal polyps (op
31 BACKGROUND &
AIMS: Activating mutations in KRAS are detected in most
32 BACKGROUND &
AIMS: Administration of tryptophan and some of its metab
33 BACKGROUND &
AIMS: Adult stem cells have been proposed to be quiescen
34 BACKGROUND &
AIMS: After careful pilot studies and planning, the nati
35 BACKGROUND &
AIMS: Agents that induce an immune response against tumo
36 BACKGROUND &
AIMS: Alagille syndrome is a genetic disorder characteri
37 BACKGROUND &
AIMS: Algorithms for diagnosis of malignant common bile
38 BACKGROUND &
AIMS: Almost all colorectal polyps </= 5 mm are benign,
39 BACKGROUND &
AIMS: Alterations in signaling pathways that regulate re
40 BACKGROUND &
AIMS: Although interleukin 28B (interferon, lambda 3) (I
41 BACKGROUND &
AIMS: Although the adenoma detection rate is used as a m
42 BACKGROUND &
AIMS: Although there is a genetic predisposition to colo
43 BACKGROUND &
AIMS: Although tumor necrosis factor (TNF) antagonists r
44 BACKGROUND &
AIMS: Although we are beginning to understand where, whe
45 BACKGROUND &
AIMS: Among patients with large colorectal sessile polyp
46 BACKGROUND &
AIMS: Among subjects screened for colorectal cancer (CRC
47 BACKGROUND &
AIMS: Approximately 10% of children on the liver transpl
48 BACKGROUND &
AIMS: Approximately 50% of all patients with pancreatic
49 BACKGROUND &
AIMS: Ascites are the most common complication of cirrho
50 BACKGROUND &
AIMS: Aspirin reduces the incidence of and mortality fro
51 BACKGROUND &
AIMS: Autosomal recessive polycystic kidney disease (ARP
52 BACKGROUND &
AIMS: Basiliximab is a chimeric monoclonal antibody that
53 BACKGROUND &
AIMS: Cardiovascular disease (CVD) is the leading cause
54 BACKGROUND &
AIMS: CD4+ T-regulatory (Treg) cells suppress immune res
55 BACKGROUND &
AIMS: Celiac disease is a chronic small intestinal infla
56 BACKGROUND &
AIMS: Celiac disease is characterized by HLA-DQ2/8-restr
57 BACKGROUND &
AIMS: Cell stress signaling pathways result in phosphory
58 BACKGROUND &
AIMS: Cell therapy offers the potential to treat gastroi
59 BACKGROUND &
AIMS: Central neuromodulators (antidepressants, antipsyc
60 BACKGROUND &
AIMS: Central obesity promotes gastroesophageal reflux,
61 BACKGROUND &
AIMS: Certain subsets of colorectal serrated polyps (SP)
62 BACKGROUND &
AIMS: Cholangiocarcinomas (CCA) are resistant to chemoth
63 BACKGROUND &
AIMS: Cholecystectomy (CCY) after an episode of choledoc
64 BACKGROUND &
AIMS: Cholera toxin can act as a modulator of the immune
65 BACKGROUND &
AIMS: Chronic hepatitis affects phenotypes of innate and
66 BACKGROUND &
AIMS: Chronic hepatitis C virus (HCV) infection is a maj
67 BACKGROUND &
AIMS: Chronic, excessive alcohol consumption leads to al
68 BACKGROUND &
AIMS: Clinical studies showed teduglutide to increase ur
69 BACKGROUND &
AIMS: Colorectal cancer (CRC) screening using quantitati
70 BACKGROUND &
AIMS: Concurrent to development of more effective drugs
71 BACKGROUND &
AIMS: Consumption of sugar is associated with obesity, t
72 BACKGROUND &
AIMS: Cytokinesis can fail during normal postnatal liver
73 BACKGROUND &
AIMS: Daclatasvir is a direct-acting antiviral agent and
74 BACKGROUND &
AIMS: De novo synthesis of guanosine diphosphate (GDP)-f
75 BACKGROUND &
AIMS: Depletion of interstitial cells of Cajal (ICCs) is
76 BACKGROUND &
AIMS: Despite inducing an inflammatory response, Helicob
77 BACKGROUND &
AIMS: Diagnosis of inflammatory bowel diseases (IBD) is
78 BACKGROUND &
AIMS: Diarrhea associated with inflammatory bowel diseas
79 BACKGROUND &
AIMS: Dietary fiber is implicated as a risk factor for d
80 BACKGROUND &
AIMS: Dietary restriction of fermentable carbohydrates (
81 BACKGROUND &
AIMS: Direct oral anticoagulant (DOAC) agents increase t
82 BACKGROUND &
AIMS: Disordered defecation is attributed to pelvic floo
83 BACKGROUND &
AIMS: Drugs that inhibit the erb-b2 receptor tyrosine ki
84 BACKGROUND &
AIMS: Dysbiosis of the intestinal microbiota has been as
85 BACKGROUND &
AIMS: Effective treatments are needed for hepatic steato
86 BACKGROUND &
AIMS: Elbasvir (an NS5A inhibitor) and grazoprevir (an N
87 BACKGROUND &
AIMS: Endoscopic ultrasound (EUS)-guided chemoablation w
88 BACKGROUND &
AIMS: Endoscopists do not routinely follow guidelines to
89 BACKGROUND &
AIMS: Endoscopy is an integral part of the investigation
90 BACKGROUND &
AIMS: Epigenetic mechanisms might be involved in the reg
91 BACKGROUND &
AIMS: Estrogen has been proposed to modulate gut inflamm
92 BACKGROUND &
AIMS: Excellent single-center outcomes of neoadjuvant ch
93 BACKGROUND &
AIMS: Fecal microbiota transplantation (FMT) is a highly
94 BACKGROUND &
AIMS: Feeding during the first months of life might affe
95 BACKGROUND &
AIMS: Few studies have examined the association between
96 BACKGROUND &
AIMS: Fibrolamellar hepatocellular carcinoma (FL-HCC) is
97 BACKGROUND &
AIMS: Foodborne illness affects 15% of the US population
98 BACKGROUND &
AIMS: For 4 decades, stigmata of recent hemorrhage in pa
99 BACKGROUND &
AIMS: For patients with Barrett's esophagus, the diagnos
100 BACKGROUND &
AIMS: Functional constipation (FC) is a common childhood
101 BACKGROUND &
AIMS: Gastric hypersensitivity (GHS) contributes to epig
102 BACKGROUND &
AIMS: Gastrointestinal (GI) diseases account for substan
103 BACKGROUND &
AIMS: Gastroparesis is a complication of diabetes with f
104 BACKGROUND &
AIMS: GATA3 is a transcription factor that regulates T-c
105 BACKGROUND &
AIMS: Gluten ingestion leads to symptoms and small intes
106 BACKGROUND &
AIMS: Healthy eating patterns assessed by diet quality i
107 BACKGROUND &
AIMS: Helicobacter pylori is remarkable for its genetic
108 BACKGROUND &
AIMS: Heme oxygenase-1 (HO-1) and its metabolic by-produ
109 BACKGROUND &
AIMS: Hepatic encephalopathy (HE) is a serious complicat
110 BACKGROUND &
AIMS: Hepatitis B virus (HBV) infects hepatocytes, but t
111 BACKGROUND &
AIMS: Hepatitis E virus (HEV) infection is a major cause
112 BACKGROUND &
AIMS: Hepatocellular adenomas (HCAs) are benign liver tu
113 BACKGROUND &
AIMS: Hepatocellular carcinoma (HCC) is a leading cause
114 BACKGROUND &
AIMS: Heritable factors contribute to the development of
115 BACKGROUND &
AIMS: Hirschsprung disease is caused by failure of enter
116 BACKGROUND &
AIMS: Human tumors and liver cancer cell lines express t
117 BACKGROUND &
AIMS: Immunodeficiency and autoimmune sequelae, includin
118 BACKGROUND &
AIMS: Improved therapy has substantially increased survi
119 BACKGROUND &
AIMS: In colorectal tumors, hypoxia causes resistance to
120 BACKGROUND &
AIMS: In healthy individuals, interactions between intes
121 BACKGROUND &
AIMS: In most patients with Parkinson's disease, gastroi
122 BACKGROUND &
AIMS: Individuals with cystic fibrosis are at increased
123 BACKGROUND &
AIMS: Individuals with cystic fibrosis are at increased
124 BACKGROUND &
AIMS: Inefficient fatty acid oxidation in mitochondria a
125 BACKGROUND &
AIMS: Infections are common in patients with severe alco
126 BACKGROUND &
AIMS: Inflammatory bowel diseases (IBD) increase risk fo
127 BACKGROUND &
AIMS: Inflammatory bowel diseases (IBDs) increase the ri
128 BACKGROUND &
AIMS: Inhibitors of the epidermal growth factor receptor
129 BACKGROUND &
AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A pro
130 BACKGROUND &
AIMS: Interactions between commensal microbes and the im
131 BACKGROUND &
AIMS: Interferon-free direct-acting antiviral (DAA) ther
132 BACKGROUND &
AIMS: Intestinal epithelial homeostasis is maintained by
133 BACKGROUND &
AIMS: Intraductal papillary mucinous neoplasias (IPMNs)
134 BACKGROUND &
AIMS: Invariant natural killer T (iNKT) cells undergo ca
135 BACKGROUND &
AIMS: Irritable bowel syndrome (IBS) is associated with
136 BACKGROUND &
AIMS: It is a challenge to deliver nucleic acids to gast
137 BACKGROUND &
AIMS: It is not clear how the complex interactions betwe
138 BACKGROUND &
AIMS: It might be possible to manipulate the intestinal
139 BACKGROUND &
AIMS: Knowledge of temporal associations between screen-
140 BACKGROUND &
AIMS: Ligand binding to inhibitory receptors on immune c
141 BACKGROUND &
AIMS: Little is known about factors associated with a su
142 BACKGROUND &
AIMS: Little is known about factors that regulate intest
143 BACKGROUND &
AIMS: Little is known about provider and health system f
144 BACKGROUND &
AIMS: Little is known about substitutions that mediate r
145 BACKGROUND &
AIMS: Little is known about the absolute risk of hepatoc
146 BACKGROUND &
AIMS: Little is known about the causes of heartburn in p
147 BACKGROUND &
AIMS: Little is known about the development of branch du
148 BACKGROUND &
AIMS: Little is known about the incidence of celiac dise
149 BACKGROUND &
AIMS: Little is known about the prevalence and burden of
150 BACKGROUND &
AIMS: Little is known about the signaling pathways that
151 BACKGROUND &
AIMS: Liver cirrhosis is complicated by bleeding from po
152 BACKGROUND &
AIMS: Liver regeneration after partial hepatectomy (PH)
153 BACKGROUND &
AIMS: Low activity of natural killer (NK) cells has been
154 BACKGROUND &
AIMS: Low estrogen levels can contribute to development
155 BACKGROUND &
AIMS: Macrophages mediate the epithelial response to Hel
156 BACKGROUND &
AIMS: Magnetic resonance imaging (MRI) techniques and ul
157 BACKGROUND &
AIMS: Maintenance and differentiation of progenitor cell
158 BACKGROUND &
AIMS: Many different types of cancer cells have chromoso
159 BACKGROUND &
AIMS: Many patients with a < 1 cm segment of columnar me
160 BACKGROUND &
AIMS: Many patients with inflammatory bowel diseases (IB
161 BACKGROUND &
AIMS: MEDI2070 is a human monoclonal antibody that selec
162 BACKGROUND &
AIMS: Microparticles released into the bloodstream upon
163 BACKGROUND &
AIMS: MicroRNAs (miRNAs) can promote or inhibit tumor gr
164 BACKGROUND &
AIMS: MicroRNAs (miRNAs) have been implicated in the dev
165 BACKGROUND &
AIMS: Multiple endoscopic bariatric therapies (EBTs) cur
166 BACKGROUND &
AIMS: Narrow-band imaging is an image-enhanced form of e
167 BACKGROUND &
AIMS: Neural stem and progenitor cells from the enteric
168 BACKGROUND &
AIMS: New-onset diabetes in patients with pancreatic can
169 BACKGROUND &
AIMS: Non-celiac gluten sensitivity is characterized by
170 BACKGROUND &
AIMS: Nonalcoholic fatty liver disease (NAFLD) is a cons
171 BACKGROUND &
AIMS: Nonalcoholic fatty liver disease (NAFLD) is associ
172 BACKGROUND &
AIMS: Nosocomial infections with Clostridium difficile p
173 BACKGROUND &
AIMS: Obesity-related insulin resistance contributes to
174 BACKGROUND &
AIMS: Paneth cell dysfunction causes deficiencies in int
175 BACKGROUND &
AIMS: Paneth cells contribute to the small intestinal ni
176 BACKGROUND &
AIMS: Patients with acute liver failure (ALF) have defec
177 BACKGROUND &
AIMS: Patients with acute liver failure (ALF) have high
178 BACKGROUND &
AIMS: Patients with celiac disease should maintain a glu
179 BACKGROUND &
AIMS: Patients with chronic hepatitis C virus (HCV) geno
180 BACKGROUND &
AIMS: Patients with chronic hepatitis C virus (HCV) infe
181 BACKGROUND &
AIMS: Patients with hepatitis C virus-associated cirrhos
182 BACKGROUND &
AIMS: Patients with inflammatory liver disease commonly
183 BACKGROUND &
AIMS: Patients with severe alcoholic hepatitis (AH) have
184 BACKGROUND &
AIMS: Patients with systemic sclerosis (SSc) have impair
185 BACKGROUND &
AIMS: People infected with human immunodeficiency virus
186 BACKGROUND &
AIMS: Pharmacologic treatment of eosinophilic esophagiti
187 BACKGROUND &
AIMS: Polymorphisms in the IL28B gene have been associat
188 BACKGROUND &
AIMS: Polymorphisms that reduce the function of nucleoti
189 BACKGROUND &
AIMS: Poorly digested, fermentable carbohydrates may ind
190 BACKGROUND &
AIMS: Preclinical studies have shown aspirin to have ant
191 BACKGROUND &
AIMS: Previous studies have suggested that dietary folic
192 BACKGROUND &
AIMS: Previous studies reported that black vs white disp
193 BACKGROUND &
AIMS: Primary sclerosing cholangitis (PSC) is an orphan
194 BACKGROUND &
AIMS: Probiotics can reduce symptoms of irritable bowel
195 BACKGROUND &
AIMS: Progression of liver fibrosis in experimental mode
196 BACKGROUND &
AIMS: Prostaglandin-endoperoxide synthase (Ptgs)2 is an
197 BACKGROUND &
AIMS: Proton pump inhibitors (PPI) are among the top 10
198 BACKGROUND &
AIMS: Proton pump inhibitors (PPI) have been associated
199 BACKGROUND &
AIMS: Proton pump inhibitors (PPIs) and histamine-2 rece
200 BACKGROUND &
AIMS: Proton pump inhibitors (PPIs) are commonly used me
201 BACKGROUND &
AIMS: Radiofrequency ablation (RFA) reduces the risk of
202 BACKGROUND &
AIMS: Recommendations for surveillance after curative su
203 BACKGROUND &
AIMS: Relative risk of colorectal cancer (CRC) decreases
204 BACKGROUND &
AIMS: Resistance of metastatic human colorectal cancer c
205 BACKGROUND &
AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose h
206 BACKGROUND &
AIMS: Screening decreases colorectal cancer (CRC) incide
207 BACKGROUND &
AIMS: Separation of newborn rats from their mothers indu
208 BACKGROUND &
AIMS: Signaling lymphocyte activation molecule (Slamf)1
209 BACKGROUND &
AIMS: Smoking, an independent risk factor for pancreatit
210 BACKGROUND &
AIMS: Statin use has been associated with a reduced inci
211 BACKGROUND &
AIMS: Stimulation of nucleotide-binding oligomerization
212 BACKGROUND &
AIMS: Studies have reported associations between proton
213 BACKGROUND &
AIMS: Studies of Clostridium difficile infections (CDIs)
214 BACKGROUND &
AIMS: Studies of the pressure response of the upper esop
215 BACKGROUND &
AIMS: Surveillance guidelines for serrated polyps (SPs)
216 BACKGROUND &
AIMS: Surveillance of patients with cirrhosis increases
217 BACKGROUND &
AIMS: Survival times vary among patients with neuroendoc
218 BACKGROUND &
AIMS: Systematic reviews have provided evidence for the
219 BACKGROUND &
AIMS: T cells are an important component for development
220 BACKGROUND &
AIMS: Tests to measure serum endomysial antibodies (EMA)
221 BACKGROUND &
AIMS: The association between prevalence of celiac disea
222 BACKGROUND &
AIMS: The canonical Wnt signaling pathway activates the
223 BACKGROUND &
AIMS: The clinical course of chronic pancreatitis is unp
224 BACKGROUND &
AIMS: The efficacy of abatacept, a selective costimulati
225 BACKGROUND &
AIMS: The enteric abundance of serotonin (5-HT), its abi
226 BACKGROUND &
AIMS: The enteric nervous system (ENS) regulates gastroi
227 BACKGROUND &
AIMS: The goal of treatment for Barrett's esophagus (BE)
228 BACKGROUND &
AIMS: The guidelines of the European Society of Pediatri
229 BACKGROUND &
AIMS: The gut microbiota affects host lipid and glucose
230 BACKGROUND &
AIMS: The IMAgINE 1 study (NCT00409682) evaluated the sa
231 BACKGROUND &
AIMS: The incidence and mortality of hepatocellular carc
232 BACKGROUND &
AIMS: The incidence of colorectal cancer (CRC) in indivi
233 BACKGROUND &
AIMS: The increase in use of anesthesia assistance (AA)
234 BACKGROUND &
AIMS: The inflammatory bowel diseases (IBD) ulcerative c
235 BACKGROUND &
AIMS: The innate immune system responds not only to bact
236 BACKGROUND &
AIMS: The mitochondrial nicotinamide adenine dinucleotid
237 BACKGROUND &
AIMS: The multiple endocrine neoplasia, type 1 (MEN1) lo
238 BACKGROUND &
AIMS: The nuclear receptor subfamily 1 group H member 4
239 BACKGROUND &
AIMS: The pathogenesis of cirrhosis, a disabling outcome
240 BACKGROUND &
AIMS: The pathogenesis of liver fibrosis involves activa
241 BACKGROUND &
AIMS: The purpose of this review is to evaluate the risk
242 BACKGROUND &
AIMS: The quality of endoscopists' colonoscopy performan
243 BACKGROUND &
AIMS: The role of sphincter of Oddi manometry (SOM) in t
244 BACKGROUND &
AIMS: The role of the intestine in the maintenance of ch
245 BACKGROUND &
AIMS: The role of tobacco smoke in the etiology of infla
246 BACKGROUND &
AIMS: The signaling molecule and transcriptional regulat
247 BACKGROUND &
AIMS: The type III interferons (IFN-lambdas: interleukin
248 BACKGROUND &
AIMS: Therapies for perianal fistulas in patients with C
249 BACKGROUND &
AIMS: There are few effective treatments for nausea and
250 BACKGROUND &
AIMS: There is controversy over the ability of transjugu
251 BACKGROUND &
AIMS: There is controversy regarding the role of the typ
252 BACKGROUND &
AIMS: There is growing interest in the use of bone marro
253 BACKGROUND &
AIMS: There is suboptimal inter-observer agreement, even
254 BACKGROUND &
AIMS: Tumor necrosis factor (TNF) is an inflammatory cyt
255 BACKGROUND &
AIMS: Tumor-suppressor proteins are inactivated by many
256 BACKGROUND &
AIMS: Use of aspirin and/or non-aspirin nonsteroidal ant
257 BACKGROUND &
AIMS: Use of monitored anesthesia care (MAC) for gastroi
258 BACKGROUND &
AIMS: Variants in the tumor necrosis factor superfamily
259 BACKGROUND &
AIMS: Video capsule endoscopy (CE) provides a noninvasiv
260 BACKGROUND &
AIMS: Visceral hypersensitivity is one feature of irrita
261 BACKGROUND &
AIMS: We analyzed DNA methylation patterns and transcrip
262 BACKGROUND &
AIMS: We assessed the diagnostic performance of magnetic
263 BACKGROUND &
AIMS: We developed comprehensive models to determine ris
264 BACKGROUND &
AIMS: We have limited knowledge about the association be
265 BACKGROUND &
AIMS: We investigated the rate and predictors of anesthe
266 BACKGROUND &
AIMS: We investigated the roles of interleukin 28A (also
267 BACKGROUND &
AIMS: We investigated whether antioxidant therapy reduce
268 BACKGROUND &
AIMS: We investigated whether patients with multiple ser
269 BACKGROUND &
AIMS: We performed a prospective study to investigate th
270 BACKGROUND &
AIMS: Western and prudent dietary patterns have been ass
271 BACKGROUND &
AIMS: Wheat amylase-trypsin inhibitors (ATIs) are nutrit
272 BACKGROUND &
AIMS: When the glial fibrillary acidic protein (GFAP) pr
273 BACKGROUND &
AIMS: Wilson disease is a disorder of copper (Cu) misbal
274 BACKGROUND &
AIMS: Zinc homeostasis in cells is maintained through ti
275 BACKGROUND&
AIMS: Proton pump inhibitors and nonsteroidal anti-infla
276 BACKGROUND, &
AIMS: Studies of primary biliary cirrhosis (PBC) phenoty
277 BACKGROUND/
AIMS: Chronic kidney disease (CKD) is an important comor
278 BACKGROUND/
AIMS: Depression is associated with an increased risk fo
279 BACKGROUND/
AIMS: Patients with vestibular disease have been observe
280 BACKGROUND/
AIMS: The aim of the present study is to probe the poten
281 fied intention-to-treat population (
baseline AIMS score >/=6 and at least one post-baseline rating).
282 (items 1-7), as assessed by blinded
central AIMS video raters.
283 ndomly assigned participants (1:1) to
either AIMS or treatment as usual (ie, containing a range of co
284 uares mean change from baseline to week 6
in AIMS dyskinesia score was -3.2 for the 80 mg/day group,
285 baseline to week 12, the least-squares
mean AIMS score improved by -3.3 points (SE 0.42) in the deut
286 Implementation
of AIMS in routine clinical HIV care is therefore recommend
287 Moreover, the improvement
of AIMS total score correlated with the increase in BDNF le
288 ning sessions of 6 h each (18 h in total)
on AIMS and a 1.5 h booster training session at the clinic
289 Motor function [Alberta Infants Motor
Scale (
AIMS)] and clinical symptoms (parental questionnaire) we
290 on the Abnormal Involuntary Movement
Scale (
AIMS) dyskinesia score (items 1-7), as assessed by blind
291 ange in Abnormal Involuntary Movement
Scale (
AIMS) score from baseline to week 12 in patients with at
292 idated by Accurate Inclusion Mass
Screening (
AIMS) and immunostaining and supported for the retinal g
293 dherence Improving self-Management
Strategy (
AIMS) compared with treatment as usual.
294 In this
study,
AIMS reduced viral load, increased QALYs, and saved reso
295 ngs from preparatory studies have shown
that AIMS is acceptable, feasible to deliver in routine care,
296 opies per mL [95% CI 35.5-55.9]) than in
the AIMS group (estimated marginal mean 35.4 copies per mL [
297 Furthermore, improvement in
the AIMS score was greatest in those with the Val/Val allele
298 The median (IQR) increase in
the AIMS score was higher in the cobalamin group than in the
299 mple comprised 221 patients; 109 assigned
to AIMS and 112 to treatment as usual.
300 nt Instrument for Mental Health Systems (
WHO-
AIMS) were included in multiple regression analyses to i